LifeMD (NASDAQ: LFMD) is scheduled to announce its fourth-quarter 2025 earnings after the market closes on Monday, March 9, 2026. Analysts anticipate that the company will report earnings of ($0.01) per share and revenue of $48.572 million for the quarter. Investors are advised to follow the details of the earnings call, which will take place at 4:30 PM ET on the same day.
The stock opened at $3.00 on Friday, reflecting fluctuations in its recent performance. Over the past year, LifeMD has experienced a fifty-two week low of $2.56 and a high of $15.84. The stock’s fifty-day moving average stands at $3.30, while the two-hundred-day moving average is $4.63. LifeMD currently holds a market capitalization of $144.42 million, a P/E ratio of -17.65, and a beta of 1.92.
Analysts’ Perspectives on LifeMD
A range of research firms have recently evaluated LifeMD’s stock performance. Lake Street Capital downgraded its price target from $14.00 to $8.00 while maintaining a “buy” rating in a report issued on November 18, 2025. Zacks Research upgraded its rating from “strong sell” to “hold” on December 19, 2025. Loop Capital also set a target price of $8.00 in a report on November 24, 2025.
Additionally, HC Wainwright reduced its price target from $13.00 to $9.00 while maintaining a “buy” rating. Weiss Ratings reaffirmed a “sell (e+)” rating on December 29, 2025. Currently, six analysts have given the stock a buy rating, two have assigned a hold rating, and one has rated it as a sell. The average rating stands at “Moderate Buy” with a consensus price target of $9.25, according to MarketBeat data.
Insider Transactions and Institutional Investments
In related news, Jessica Friedeman, the Chief Marketing Officer of LifeMD, sold 15,000 shares on December 9, 2025, at an average price of $3.61, totaling $54,150. Following this transaction, Friedeman owns 205,000 shares valued at approximately $740,050, indicating a 6.82% decrease in her ownership. This transaction was disclosed in a filing with the Securities and Exchange Commission.
Institutional investors have also been active in the market, with several altering their stakes in LifeMD. Tower Research Capital LLC increased its holdings by 110.4% during the second quarter, now owning 4,674 shares valued at $64,000. Quarry LP acquired a new position worth around $52,000 in the third quarter.
Legal & General Group Plc raised its investment by 187.4%, owning 10,144 shares valued at $138,000, after purchasing an additional 6,614 shares. Caitong International Asset Management Co. Ltd and Hudson Bay Capital Management LP also made new investments during the recent quarters. Overall, institutional investors and hedge funds own approximately 35.52% of LifeMD’s stock.
LifeMD operates as a telehealth company based in the United States, offering on-demand, membership-based virtual healthcare services. Its digital platform connects patients with board-certified healthcare providers for the diagnosis, treatment, and management of various health conditions, including men’s health, hormonal therapy, and weight management.
